<DOC>
	<DOCNO>NCT02626962</DOCNO>
	<brief_summary>This Phase 2 , single-arm study nivolumab combine ipilimumab subject previously untreated , unresectable metastatic uveal melanoma . Previous study immunotherapy show promising result synergistic combination effective tumor . This study allow characterization safety clinical activity nivolumab combine ipilimumab subject uveal melanoma .</brief_summary>
	<brief_title>Trial Nivolumab Combination With Ipilimumab Subjects With Previously Untreated Metastatic Uveal Melanoma</brief_title>
	<detailed_description>Uveal melanoma rare disease , account 0.1 % cancer death . This disease arise melanocytes uveal tract common primary intraocular tumor adult , incidence estimate 0.6 per 100,000 persons/year Western population seem remain stable time . Metastases uveal melanoma appear 6.5 % -35 % patient first decade . The clinical metastatic behavior differs cutaneous melanoma initially purely hematogenous dissemination tendency metastasize liver . Furthermore , liver almost `` sentinel lymph node '' uveal melanoma , affect 95 % patient sole site metastasis case . This specific ocular-hepatic tropism remain unexplained . When liver metastases develop , prognosis poor life expectancy reduce less 6 month absence treatment . Only prognostic factor survival identify . Age , short time interval metastasis development , tumor burden liver show negative impact survival , whereas patient diagnose regular follow-up survive significantly longer , probably due early diagnosis . Several loco-regional treatment option consider metastasis confine liver , include partial hepatic resection radiofrequency ablation . Curative resection possible small fraction patient due number , location size metastasis . Systemic chemotherapy usually unsuccessful metastatic uveal melanoma result recently review show Overall Response Rate 4,6 % 95 % CI 3.3-6.3 % . There proof conventional chemotherapy prolongs survival study report OS 5 12 month . Most therapy derive experience extrapolate cutaneous melanoma . Only chemotherapeutic regimen study phase II trial bleomycin /vincristine/ lomustine /dacarbazine ( BOLD ) , fotemustine,9-nitrocamptothecin , temozolomide , bendamustine , gemcitabine/treosulfan , cisplatin/gemcitabine/treosulfan , dacarbazine/treosulfan poor result range 0 15 % response rate le 12 month overall survival first line therapy . A phase III trial randomize patient chemotherapy Best Suportive Care ( BSC ) expect perform difficulty recruit due low incidence disease . In hand , best understand biology cancer disease allow u identify pathway important mechanism proliferation , survival dissemination . Recently Guanine Nucleotide-Binding Protein G ( GNAQ ) gene oncogenic mutation identify close 50 % primary uveal melanoma . The emergence newer agent target pathway ( selumetinib , sunitinib , imatinib , vorinostat , antiangiogenics ) result multiple small study date fail show clear superiority chemotherapy . To summarize , patient metastatic uveal melanoma include clinical trial evaluate option new agent potentially less toxicity great efficacy conventional chemotherapy .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>1 . Written informed consent must provide ; 2 . Patients must histological diagnosis uveal melanoma ; 3 . Progressive metastatic disease baseline . Progressive disease define new progressive lesion crosssectional imaging ; 4 . Age &gt; 18 year ; 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 ; 6 . Measurable disease CT MRI per RECIST 1.1 criterion ; 1 . Prior systemic treatment metastatic uveal melanoma . 2 . Prior malignancy active within previous 3 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix breast , incidental prostate cancer . 3 . Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome Myasthenia Gravis ) . Subjects vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll . 4 . Any underlying medical psychiatric condition , opinion investigator make administration nivolumab ipilimumab hazardous obscure interpretation Advers Events ( AEs ) , condition associate frequent diarrhea . 5 . Any nononcology vaccine therapy use prevention infectious disease ( 1 month dose nivolumab ipilimumab ) . 6 . A history prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation immune checkpoint pathway . 7 . Concomitant therapy following : Interleukin ( IL ) 2 , interferon , nonstudy immunotherapy regimen ; cytotoxic chemotherapy ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid , define &gt; 10mg daily prednisone equivalent . Inhaled topical steroid , adrenal replacement dos &gt; 10 mg daily prednisone equivalent permit absence active autoimmune disease . 8 . Active brain metastasis leptomeningeal metastasis . Subjects brain metastasis eligible treated magnetic resonance imaging ( MRI ) evidence progression least 8 week treatment complete within 28 day prior first dose study drug administration . There must also requirement immunosuppressive dos systemic corticosteroid ( &gt; 10 mg/day prednisone equivalent ) least 2 week prior study drug administration . 9 . Women childbearing potential ( WOCBP ) define , : unwilling unable use acceptable method contraception avoid pregnancy entire study period least 8 week cessation study drug , positive pregnancy test baseline , pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>melanoma</keyword>
</DOC>